Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Research & Development (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Research & Development for 6 consecutive years, with $6.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 11.6% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.8 million through Dec 2025, up 73.11% year-over-year, with the annual reading at $29.8 million for FY2025, 73.11% up from the prior year.
  • Research & Development for Q4 2025 was $6.4 million at Inhibikase Therapeutics, down from $7.6 million in the prior quarter.
  • The five-year high for Research & Development was $13.6 million in Q4 2023, with the low at $2.4 million in Q2 2021.
  • Average Research & Development over 5 years is $4.7 million, with a median of $3.2 million recorded in 2021.
  • The sharpest move saw Research & Development skyrocketed 2516.39% in 2021, then crashed 47.06% in 2024.
  • Over 5 years, Research & Development stood at $3.4 million in 2021, then decreased by 9.91% to $3.1 million in 2022, then surged by 344.91% to $13.6 million in 2023, then plummeted by 47.06% to $7.2 million in 2024, then dropped by 11.6% to $6.4 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $6.4 million, $7.6 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.